iShares US Pharmaceuticals ETF
92 hedge funds and large institutions have $60.8M invested in iShares US Pharmaceuticals ETF in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 32 reducing their positions, and 11 closing their positions.
43% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $800K
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
3% less funds holding
Funds holding: 95 → 92 (-3)
15.08% less ownership
Funds ownership: 81.14% → 66.05% (-15%)
31% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 32
37% less capital invested
Capital invested by funds: $96.2M → $60.8M (-$35.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.05M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$2.64M |
| 3 |
SRSA
S.R. Schill & Associates
Mercer Island,
Washington
|
+$1.46M |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$424K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$281K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$15.1M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$5.4M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.29M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.45M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.18M |
IHE Hedge Fund Activity: Q1 2020 in Review
92 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2020, worth a combined $60.8M — down 37% from $96.2M a quarter earlier.
Fund positioning in IHE was balanced in Q1 2020: 11 funds opened new positions, 11 closed out, 22 added to existing stakes and 32 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $3.05M. The largest seller was Goldman Sachs, cutting an estimated $15.1M.
- 92 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2020, down from 95 in Q4 2019.
- Funds reported $60.8M of iShares US Pharmaceuticals ETF stock for Q1 2020, down 37% quarter-over-quarter.
- 11 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2020 and 11 closed out, a net change of 0 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2020 was Susquehanna International Group, an estimated $3.05M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2020 was Goldman Sachs, an estimated $15.1M sold.
Based on aggregated 13F filings for Q1 2020.